ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$8.79
-0.37 (-4.04%)
▼
5d:
-6.69%
30d:
-1.57%
90d:
-0.9%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ZVRA is down 4.4% this week, but smart money is accumulating calls. Top strike: $12 2026-05-15 with 135 OI. Call ratio: 78% View Scanner →
Strength: 5.0/10
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ZVRA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ZVRA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.89
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$23.53
62.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $8.79, which is considered slightly low relative to its 30-day fair value range of $8.76 to $9.87. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.0) compared to its historical average (12.8). Remarkably, the market is currently pricing in an annual earnings decline of 22.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZVRA is in a uptrend. The price is currently testing key support at $8.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.78 (+148.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ZVRA is in a uptrend. The price is currently testing key support at $8.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.78 (+148.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$8.76 -
$9.87
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.6%
Protect Your Profits
Holding ZVRA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 148.7% below Wall St target ($22.78)
- CAUTION: Recommendation downgraded due to -6.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$8.76 -
$9.87
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.76
(8.6%)
Support & Resistance Levels
Support Level
$8.81
Resistance Level
$10.11
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.03
Wall Street Target
$22.78
(+148.7%)
Revenue Growth (YoY)
183.4%
Profit Margin
78.2%
Valuation Discount vs History
-22.2% cheaper
PE vs Historical
6.0 vs 12.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.2%
(market-implied from PE analysis)
1-Year Target
$8.24
(-10%)
2-Year Target
$7.42
(-19%)
3-Year Target
$6.68
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→13)
$14.18
(+55%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 206.3%)
$114.91
(+1155%)
Base:
(SPY PE: 6.0, Growth: 206.3%)
$30.91
(+238%)
Bear:
(PE: 5.1, Growth: 206.3%)
$26.28
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (7x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 6.84 | Current EPS (TTM): $1.35
Bull Case
$11.43
(+21%)
Analyst growth 12.6%, PE expands to 7.5
Base Case
$10.39
(+10%)
Market implied 12.6%, PE stable at 6.8
Bear Case
$6.28
(-33%)
Severe decline -20.0%, PE contracts to 5.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.0 to 12.8
Stabilization Target:
$19.46
(+112.4%)
PE Expansion Potential:
+112.4%
Share & Embed Analysis
Last updated: March 30, 2026 3:04 PM ET
Data refreshes hourly during market hours. Next update: 4:04 PM
Data refreshes hourly during market hours. Next update: 4:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Joshua Schafer
SELL
10500 shares
2026-02-03
Timothy J Sangiovanni
SELL
3000 shares
2026-02-03
Neil F Mcfarlane
SELL
91000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 50 HOLD |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
